Abstract
Angiotensin-converting enzyme (ACE) has a critical role in cardiovascular function by cleaving the carboxy terminal His-Leu dipeptide from angiotensin I to produce a potent vasopressor octapeptide, angiotensin II. Inhibitors of ACE are a first line of therapy for hypertension, heart failure, myocardial infarction and diabetic nephropathy. Notably, these inhibitors were developed without knowledge of the structure of human ACE, but were instead designed on the basis of an assumed mechanistic homology with carboxypeptidase A1. Here we present the X-ray structure of human testicular ACE and its complex with one of the most widely used inhibitors, lisinopril (N2-[(S)-1-carboxy-3-phenylpropyl]-l-lysyl-l-proline; also known as Prinivil or Zestril), at 2.0 Å resolution. Analysis of the three-dimensional structure of ACE shows that it bears little similarity to that of carboxypeptidase A, but instead resembles neurolysin2 and Pyrococcus furiosus carboxypeptidase3—zinc metallopeptidases with no detectable sequence similarity to ACE. The structure provides an opportunity to design domain-selective ACE inhibitors that may exhibit new pharmacological profiles.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout



Similar content being viewed by others
References
Cushman, D. W., Cheung, H. S., Sabo, E. F. & Ondetti, M. A. Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. Biochemistry 16, 5484–5491 (1977)
Brown, C. K. et al. Structure of neurolysin reveals a deep channel that limits substrate access. Proc. Natl Acad. Sci. USA 98, 3127–3132 (2001)
Arndt, J. W. et al. Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus. Structure 10, 215–224 (2002)
Soubrier, F. et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl Acad. Sci. USA 85, 9386–9390 (1988)
Williams, T. A., Corvol, P. & Soubrier, F. Identification of two active site residues in human angiotensin I-converting enzyme. J. Biol. Chem. 269, 29430–29434 (1994)
Wei, L., Clauser, E., Alhenc-Gelas, F. & Corvol, P. The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J. Biol. Chem. 267, 13398–13405 (1992)
Junot, C. et al. RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J. Pharmacol. Exp. Ther. 297, 606–611 (2001)
Esther, C. R. et al. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J. Clin. Invest. 99, 2375–2385 (1997)
Ehlers, M. R. W., Fox, E. A., Strydom, D. J. & Riordan, J. F. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc. Natl Acad. Sci. USA 86, 7741–7745 (1989)
Yu, X. C. et al. Identification of N-linked glycosylation sites in human testis angiotensin-1 converting enzyme and expression of an active deglycosylated form. J. Biol. Chem. 272, 3511–3519 (1997)
Chubb, A. J., Schwager, S. L. U., Woodman, Z. L., Ehlers, M. R. W., Sturrock, E. D. . Biochem. Biophys. Res. Commun. 297, 1225–1230 (2002)
Ehlers, M. R. W. & Riordan, J. F. Angiotensin-converting enzyme: zinc- and inhibitor-binding stoichiometries of the somatic and testis isozymes. Biochemistry 30, 7118–7126 (1991)
Bünning, P. & Riordan, J. F. Activation of angiotensin converting enzyme by monovalent anions. Biochemistry 22, 110–116 (1983)
Shapiro, R., Holmquist, B. & Riordan, J. F. Anion activation of angiotensin converting enzyme: dependence on nature of substrate. Biochemistry 22, 3850–3857 (1983)
Jaspard, E., Wei, L. & Alhenc-Gelas, F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (Kininase II). J. Biol. Chem. 268, 9496–9503 (1993)
Liu, X., Fernandez, M., Wouters, M. A., Heyberger, S. & Husain, A. Arg-1098 is critical for the chloride dependence of human angiotensin-1 converting enzyme C-domain catalytic activity. J. Biol. Chem. 276, 33518–33525 (2001)
Holm, L. & Sander, C. Protein folds and families: sequence and structure alignments. Nucleic Acids Res. 27, 244–247 (1999)
Corvol, P. & Williams, T. A. in Handbook of Proteolytic Enzymes (eds Barrett, A. J., Rawlings, N. D. & Woessner, J. F.) 1066–1076 (Academic, London, 1998)
Skidgel, R. A., Engelbrecht, S., Johnson, A. R. & Erdos, E. G. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5, 769–776 (1984)
Patchett, A. A. et al. A new class of angiotensin-converting enzyme inhibitors. Nature 288, 280–283 (1980)
Patchett, A. A. & Cordes, E. H. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin converting enzyme. Adv. Enzymol. 57, 1–84 (1985)
Bernstein, K. E., Welsh, S. L. & Inman, J. K. A deeply recessed active site in angiotensin converting enzyme is indicated from the binding characteristic of biotin-spacer-inhibitor reagents. Biochem. Biophys. Res. Commun. 167, 310–317 (1990)
Bunning, P., Holmquist, B. & Riordan, J. F. Functional residues at the active site of angiotensin converting enzyme. Biochem. Biophys. Res. Commun. 83, 1442–1449 (1978)
Otwinowski, M. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997)
Collaborative computational project Number 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D 50, 760–763 (1994)
De La Fortelle, E. & Bricogne, G. Maximum-likelihood heavy-atom parameters refinement in the MIR and MAD methods. Methods Enzymol. 276, 472–494 (1997)
Abrahams, J. P. & Leslie, A. G. W. Methods used in structure determination of bovine mitochondrial F1 ATPase. Acta Crystallogr. D 52, 110–119 (1996)
Brünger, A. T. et al. Crystallography & N. M. R. system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905–921 (1998)
Merritt, E. A. & Bacon, D. J. Raster 3D: photorealistic molecular graphics. Methods Enzymol. 277, 505–524 (1997)
Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrogen atoms. Proteins Struct. Funct. Genet. 11, 281–296 (1991)
Acknowledgements
This work was supported by a Wellcome Trust grant to K.R.A., a Collaborative Research Initiative Grant to E.D.S. and K.R.A., and a National Research Foundation Grant to E.D.S. We thank M. Walsh, H. Belrahli and A. Thompson at ESRF, and L. Duke, J. Nicholson, M. McDonald, P. Rizkallah and M. Papiz at SRS for their help during X-ray data collection. We also thank R. Shapiro, J. Riordan and M. Ehlers for constructive criticism of the manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare that they have no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Natesh, R., Schwager, S., Sturrock, E. et al. Crystal structure of the human angiotensin-converting enzyme–lisinopril complex. Nature 421, 551–554 (2003). https://doi.org/10.1038/nature01370
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature01370
This article is cited by
-
Algorithm selection for protein–ligand docking: strategies and analysis on ACE
Scientific Reports (2023)
-
Interaction of hemorphins with ACE homologs
Scientific Reports (2023)
-
Antioxidant and Antihypertensive Properties of Neem Seed Protein Hydrolysates: The Effects of Hydrolytic Enzyme Type and Peptide Size
International Journal of Peptide Research and Therapeutics (2023)
-
Evaluation of tea (Camellia sinensis L.) phytochemicals as multi-disease modulators, a multidimensional in silico strategy with the combinations of network pharmacology, pharmacophore analysis, statistics and molecular docking
Molecular Diversity (2023)
-
Valorization of Salmo salar Skin Waste for the Synthesis of Angiotensin Converting Enzyme-1 (ACE1) Inhibitory Peptides
Waste and Biomass Valorization (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.